AMPH vs. ELAN, PTCT, ADMA, ZLAB, RNA, OGN, ACLX, SWTX, RARE, and AKRO
Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Elanco Animal Health (ELAN), PTC Therapeutics (PTCT), ADMA Biologics (ADMA), Zai Lab (ZLAB), Avidity Biosciences (RNA), Organon & Co. (OGN), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.
Amphastar Pharmaceuticals vs.
Elanco Animal Health (NYSE:ELAN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Elanco Animal Health has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
Amphastar Pharmaceuticals received 251 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 65.99% of users gave Amphastar Pharmaceuticals an outperform vote while only 54.44% of users gave Elanco Animal Health an outperform vote.
Amphastar Pharmaceuticals has a net margin of 21.80% compared to Elanco Animal Health's net margin of 4.60%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Elanco Animal Health's return on equity.
97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 0.6% of Elanco Animal Health shares are held by company insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Elanco Animal Health had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 10 mentions for Elanco Animal Health and 9 mentions for Amphastar Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.94 beat Amphastar Pharmaceuticals' score of 0.62 indicating that Elanco Animal Health is being referred to more favorably in the media.
Elanco Animal Health presently has a consensus target price of $15.17, suggesting a potential upside of 42.75%. Amphastar Pharmaceuticals has a consensus target price of $43.50, suggesting a potential upside of 54.39%. Given Amphastar Pharmaceuticals' higher possible upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Elanco Animal Health.
Amphastar Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Summary
Amphastar Pharmaceuticals beats Elanco Animal Health on 10 of the 18 factors compared between the two stocks.
Get Amphastar Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amphastar Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AMPH) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy AMPH Stock Free AMPH Stock Alerts